CFTR triple modulator

Deutivacaftor with tezacaftor and vanzacaftor

Brand names: Alyftrek

Adult dose

Dose: Per body weight per SmPC; once-daily oral combination

Route: Oral

Frequency: OD with fat-containing meal

Clinical pearls

Cystic fibrosis with at least one F508del or other responsive mutation — extends elexacaftor-tezacaftor-ivacaftor (Kaftrio) modulator paradigm
NICE TA evaluation; UK CF Trust
Specialist CF centre — multidisciplinary

Contraindications

Severe hepatic impairment
Concurrent strong CYP3A4 inducers
Hypersensitivity

Side effects

Headache
Diarrhoea
Rash
Hepatotoxicity (LFT elevations)
Cataracts (paediatrics)
Rare: lens opacities, depression

Interactions

Strong CYP3A4 inhibitors/inducers

Monitoring

LFTs
FEV₁
Sweat chloride
Eye examination (paediatric)
Pulmonary exacerbations

Reference: BNF; NICE TA evaluation; UK CF Trust; SmPC; https://bnf.nice.org.uk/drugs/deutivacaftor-with-tezacaftor-and-vanzacaftor/. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma

Pathways